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Proteins are highly evolved nanomachines
that carry out the work of the cell. Biologic
information is transmitted both by and through
proteins. Just as proteins are the functional
elements of the organism, the field of clinical
proteomics is an effector arm of the upcoming
revolution in molecular medicine. Recent
advances in proteomic technology have yielded
biologic discoveries and pathologic insights at
a rapid pace. Proteomics has opened a treasure
chest of candidate biomarkers that were
never before known to exist in the blood.
Protein–protein interactions, posttranslational
modifications, and entire proteomic circuits
have become the new scaffolding for drug
target discovery. Investigators have graduated
from tissue-culture cell lines, and are now
routinely applying proteomics to human
tissue samples. The mission of Clinical Pro-
teomics is to provide a scholarly forum for
novel scientific research in the field of trans-
lational proteomics. The special emphasis of
Clinical Proteomics is the application of pro-
teomic technology to clinical research. Areas of
emphasis will include the following:
• Clinical sample collection and handling
to preserve proteins and posttranslational
modifications.
• New technology for protein-based clinical
bioassays and clinical chemistry assays.
• Translational pathology related to proteomics.
• Bioinformatic tools and protein circuit-
building.
• Biomarker discovery and validation from
clinical samples.
• Signal transduction pathway profiling in
clinical tissue samples.
• Discovery of new drug targets from clinical
samples.
Clinical Proteomics Journal
Copyright ©Humana Press Inc.
All rights of any nature whatsoever are reserved.
ISSN 1542-6416/04/01:1–2/$25.00
Clinical Proteomics
From Discovery to Individual Therapy
Lance A. Liotta,1 and Emanuel F. Petricoin III*,2
1NCI/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National
Cancer Institute, Bethesda, MD, 20892
*,2NCI/FDA Cinical Proteomics Program, Office of Cell and Gene Therapy, Center for Biologics Evalua-
tion and Research, Food and Drug Administration, Bethesda, MD, 20892
2 ___________________________________________________________________________ Liotta and Petricoin
Clinical Proteomics _______________________________________________________________ Volume 1, 2004
• Use of proteomic technologies in the
drug development pipeline (hit to lead
screening and lead optimization and pre-
clinical screening).
• Use of proteomic technologies to monitor
prognosis, therapeutic end points, toxicity,
and efficacy.
• Clinical trials using proteomic monitoring
• Clinical trials using proteomics to individu-
alize therapy.
This inaugural issue of Clinical Proteomics
is a showcase of scientific research spanning
discovery, functional analysis and biomarker
profiling.
